AG
CPRX

Aperio Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Aperio Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$47K Sell
14,180
-6,742
-32% -$22.6K ﹤0.01% 2414
2020
Q3 		$62K Buy
20,922
+6,776
+48% +$26.5K ﹤0.01% 2347
2020
Q2 		$65K Buy
+14,146
New +$63.6K ﹤0.01% 2291
2019
Q3 		– Sell
-192
Closed -$1K – 2408
2019
Q2 		$1K Buy
+192
New +$829 ﹤0.01% 2972

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Aperio Group's CPRX Position: Q4 2020 in Review

Aperio Group reduced its Catalyst Pharmaceutical (CPRX) stake by 32% in Q4 2020, selling an estimated $22.6K and leaving 14,180 shares worth $47K. The position accounts for ﹤0.01% of the portfolio, ranked #2414.

Aperio Group first reported a position in CPRX in Q2 2019 and has held it in 4 quarters since. The position peaked at $65K in Q2 2020. 135 funds tracked by Wall St. Rank hold CPRX as of Q4 2020.

  • Aperio Group held 14,180 shares of Catalyst Pharmaceutical worth $47K as of Q4 2020.
  • Aperio Group sold 6,742 Catalyst Pharmaceutical shares in Q4 2020, an estimated $22.6K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2414 holding.
  • Aperio Group first reported a position in Catalyst Pharmaceutical in Q2 2019 and has held it in 4 quarters since.
  • Aperio Group's Catalyst Pharmaceutical position peaked at $65K in Q2 2020.
  • 135 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.